AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03595826
Drug: Neurostimulant pharmaceutical drugs
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
Trial: NCT02690025
Drug: ZP1848
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03742232
Drug: PEG3350
RxNorm normalized name: PEG3350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
Trial: NCT00105521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to sarizotan will be administered twice daily.
Trial: NCT01536535
Drug: Oral Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with oral corticosteroids
Trial: NCT03456843
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Trial: NCT00094497
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02003664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
Trial: NCT01485991
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
Trial: NCT02091206
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Trial: NCT02091206
Drug: GWP42003-P 10 mg/kg/day Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Trial: NCT01819818
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
Trial: NCT02307162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy solution
Trial: NCT01475370
Drug: OCV-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose.
Trial: NCT02538471
Drug: Study Drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
Trial: NCT02131155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT01887418
Drug: QuickShot™ - 50 mg Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuickShot™ for the delivery of testosterone
Trial: NCT01887418
Drug: QuickShot™ - 100 mg Treatment A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuickShot™ for the delivery of testosterone
Trial: NCT01887418
Drug: Delatestryl 200 mg IM Treatment C
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT04611724
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
Trial: NCT04761341
Drug: NUTROF TOTAL
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 per day over a course of 3 months
Trial: NCT03412513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po daily for 8 weeks to Placebo comparator group.
Trial: NCT02527863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Unikalk pr day for 1 day
Trial: NCT00730392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
Trial: NCT03604653
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg/m2@T0
Trial: NCT03663543
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Trial: NCT00433498
Drug: pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg daily oral tablet taken for a maximum of 2 years
Trial: NCT01178281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
Trial: NCT02646189
Drug: REP 2139-Ca
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
Trial: NCT02977780
Drug: QBS10072S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBS10072S administered intravenously
Trial: NCT00243217
Drug: SPM 936
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02160678
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
Trial: NCT02160678
Drug: Tazorac Cream, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
Trial: NCT00626158
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
Trial: NCT02706834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-828 placebo-matching oral solution
Trial: NCT03398434
Drug: MAA868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MAA868 doses, single administration, subcutaneous,
Trial: NCT02223507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255515
Drug: conventional treatment for schizophrenia
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: various standard therapies
Trial: NCT00609245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
Trial: NCT01535196
Drug: Vigantol oil and MCT oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
Trial: NCT00218075
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01631825
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Trial: NCT02068352
Drug: OPA-15406
RxNorm normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPA-15406 topical ointment
Trial: NCT00119314
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01141153
Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent
Trial: NCT03986944
Drug: Placebo capsule to match Add-back capsule
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT01233492
Drug: boron phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03327051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match omeprazole
Trial: NCT01399684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Trial: NCT00546702
Drug: Insuline Glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04073849
Drug: EPOGEN® (epoetin alfa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug
Trial: NCT00733551
Drug: GSK962040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
Trial: NCT00355602
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00355602
Drug: Coamoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00355602
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02608697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02186496
Drug: CKD-330 8/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03817346
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator single ascending dose
Trial: NCT02802683
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continous infusion of normal saline
Trial: NCT00658697
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Trial: NCT01641289
Drug: No Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.
Trial: NCT01963442
Drug: Placebo (for Augmentin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets 3 times a day for 5 days from Day 3
Trial: NCT01963442
Drug: Beta-Lactams
RxNorm normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered from Day 0 to Day 3
Trial: NCT04092621
Drug: Rate-control therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
Trial: NCT01247870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01960114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
Trial: NCT01256372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; intravenous infusion
Trial: NCT00271466
Drug: DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04348383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 250 cc every 6 hours for 7 or15 days
Trial: NCT02874248
Drug: 15 mg E4/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
Trial: NCT02874248
Drug: 30 mg E4/6 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
Trial: NCT02874248
Drug: Visually matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
Trial: NCT02874248
Drug: 75 mg E4/15 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
Trial: NCT00451555
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT01141153
Drug: Acetylsalicylic Acid + clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent.
Trial: NCT02469077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Trial: NCT01040403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04697641
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice a day for two weeks
Trial: NCT01284634
Drug: GWP42003 200 mg/day Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Trial: NCT01284634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
Trial: NCT02946450
Drug: Other: Not applicable-observational study
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01732588
Drug: 120 mg OZ439 caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
Trial: NCT00784277
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule for 14 days
Trial: NCT00784277
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and capsules 2 x a day for 28 days
Trial: NCT00187135
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline
Trial: NCT00187135
Drug: L.M.X4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
Trial: NCT01072396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
Trial: NCT04299971
Drug: Methotrexate Tablets
RxNorm normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead.
Trial: NCT00309621
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01878188
Drug: BC-819/PEI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation
Trial: NCT01865175
Drug: ionic iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
Trial: NCT00475735
Drug: MK0249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
Trial: NCT00475735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
Trial: NCT01076322
Drug: Meptin® Swinghaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)
Trial: NCT01076322
Drug: Ventolin® MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)
Trial: NCT00510783
Drug: Fosphenytoin
RxNorm normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
Trial: NCT01920399
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
Trial: NCT01391533
Drug: SAR125844
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT02299414
Drug: Anti-hypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
Trial: NCT00224809
Drug: Angiotensin-Converting Enzyme Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00224809
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02857309
Drug: Optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT using standard heart failure (HF) drugs
Trial: NCT02277587
Drug: Conventional glucocorticoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets: 20-25-30- 37.5 mg
Trial: NCT01591655
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of vehicle into the study eye QID for 14 days.
Trial: NCT00024102
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
Trial: NCT00890214
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.